Seokjoon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seokjoon Lee has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Jungyeob Ham
Marine Chemomics Laboratory, Medicine Center, Korea Institute of Science and Technology, Gangneung 210-340, Republic of Korea
2 shared publications- Qian Wang
Department of Chemistry and Biochemistry, University of South Carolina, Columbia, USA
2 shared publications Sangtae Oh
Department of Basic Science, Kwandong University College of Medicine, Gangneung 210-701, Republic of Korea
2 shared publicationsWoon-Seob Shin
2 shared publicationsByong-Gon Park
Department of physiology, Kwandong University College of Medicine, Gangneung 210-701, Republic of Korea
1 shared publicationChan Mug Ahn
Department of Basic Sciences and Institute of Basic Medical Science, Wonju College of Medicine, Yonsei University, Wonju 220-701, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 25 February 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (3) , 312
Recent Trends in Prostate Biopsy Complication Rates and the Role of Aztreonam in Periprocedural Antimicrobial Prophylaxis—A Nationwide Population-Based Study from Korea
An increase in the rate of complications after prostate biopsy (PB) due to increased antibiotic-resistant bacteria is a global issue. We report the safety of aztreonam as a prophylactic antibiotic in patients undergoing PB. We investigated the complication rates according to several antibiotic regimens, including aztreonam. We hypothesized that PB complications increased following a rise in antibiotic-resistant bacteria. We examined the annual rates of complications among patients in our hospital (clinical cohort) and the Korea Health Insurance Review and Assessment Service (HIRA) cohort. Data regarding complications, hospitalization, emergency room (ER) visits, and febrile urinary tract infections occurring within 2 weeks after PB were recorded. The rate of complications was significantly lower in patients who received oral quinolone and intravenous aztreonam than in those who received oral quinolone. The complication rates did not increase throughout the study period. Additionally, 1754 patients from the HIRA cohort were included. The rates of complications, hospitalizations, and ER visits did not increase among these patients. Oral quinolone combined with intravenous aztreonam reduced the rate of febrile complications compared to quinolone alone and was safe to use after PB. Therefore, we recommend intravenous aztreonam with oral quinolone as a prophylactic antibiotic regimen before PB.
- 25 February 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (3) , 312
Open AccessRecent Trends in Prostate Biopsy Complication Rates and the Role of Aztreonam in Periprocedural Antimicrobial Prophylaxis—A Nationwide Population-Based Study from Korea
An increase in the rate of complications after prostate biopsy (PB) due to increased antibiotic-resistant bacteria is a global issue. We report the safety of aztreonam as a prophylactic antibiotic in patients undergoing PB. We investigated the complication rates according to several antibiotic regimens, including aztreonam. We hypothesized that PB complications increased following a rise in antibiotic-resistant bacteria. We examined the annual rates of complications among patients in our hospital (clinical cohort) and the Korea Health Insurance Review and Assessment Service (HIRA) cohort. Data regarding complications, hospitalization, emergency room (ER) visits, and febrile urinary tract infections occurring within 2 weeks after PB were recorded. The rate of complications was significantly lower in patients who received oral quinolone and intravenous aztreonam than in those who received oral quinolone. The complication rates did not increase throughout the study period. Additionally, 1754 patients from the HIRA cohort were included. The rates of complications, hospitalizations, and ER visits did not increase among these patients. Oral quinolone combined with intravenous aztreonam reduced the rate of febrile complications compared to quinolone alone and was safe to use after PB. Therefore, we recommend intravenous aztreonam with oral quinolone as a prophylactic antibiotic regimen before PB.
- 28 April 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (12) , 3573-3577
Synthesis of substituted triazolyl curcumin mimics that inhibit RANKL-induced osteoclastogenesis
- 28 April 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (12) , 3573-3577
Synthesis of substituted triazolyl curcumin mimics that inhibit RANKL-induced osteoclastogenesis
- 1 March 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (5) , 1481-1483
Synthesis of sulfonyl curcumin mimics exerting a vasodilatation effect on the basilar artery of rabbits
- 1 March 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (5) , 1481-1483
Synthesis of sulfonyl curcumin mimics exerting a vasodilatation effect on the basilar artery of rabbits
- 12 October 2006
- Published by Wiley in Medicinal Research Reviews
- Vol. 27 (4) , 553-573
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B
Protein tyrosine phosphatases (PTPs), a large family of signaling enzymes, play essential roles in intracellular signal transduction by regulating the cellular level of tyrosine phosphorylation to control cell growth and differentiation, metabolism, cell migration, gene transcription, ion‐channel activity, immune response, cell apoptosis, and bone development. Among all PTPs, protein tyrosine phosphatase 1B (PTP1B) plays a seminal role in cellular signaling and in many human diseases, including cancer, diabetes, and obesity. Therefore, small molecular inhibitors of PTP1B can be promising drug candidates. Because of the structural homologies in many families of PTPs, it is a challenging task to find inhibitors specific to each PTP. Recent studies suggested that secondary binding pockets or peripheral binding sites around the conserved active site should be exploited to design novel potent and selective PTP1B inhibitors. In this review, we discuss the structural and biological features of small molecular PTP1B‐specific inhibitors, with particular emphasis on small molecular inhibitors targeting PTP1B over the other PTPs that have been synthesized in the past 4 years. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 4, 553–573, 2007
- 12 October 2006
- Published by Wiley in Medicinal Research Reviews
- Vol. 27 (4) , 553-573
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B
Protein tyrosine phosphatases (PTPs), a large family of signaling enzymes, play essential roles in intracellular signal transduction by regulating the cellular level of tyrosine phosphorylation to control cell growth and differentiation, metabolism, cell migration, gene transcription, ion‐channel activity, immune response, cell apoptosis, and bone development. Among all PTPs, protein tyrosine phosphatase 1B (PTP1B) plays a seminal role in cellular signaling and in many human diseases, including cancer, diabetes, and obesity. Therefore, small molecular inhibitors of PTP1B can be promising drug candidates. Because of the structural homologies in many families of PTPs, it is a challenging task to find inhibitors specific to each PTP. Recent studies suggested that secondary binding pockets or peripheral binding sites around the conserved active site should be exploited to design novel potent and selective PTP1B inhibitors. In this review, we discuss the structural and biological features of small molecular PTP1B‐specific inhibitors, with particular emphasis on small molecular inhibitors targeting PTP1B over the other PTPs that have been synthesized in the past 4 years. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 4, 553–573, 2007
- 1 September 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (17) , 4596-4599
Synthesis and anti-angiogenesis activity of coumarin derivatives
- 1 September 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (17) , 4596-4599
Synthesis and anti-angiogenesis activity of coumarin derivatives
- 7 May 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (12) , 2009-2012
A study on the synthesis of antiangiogenic (+)-coronarin A and congeners from (+)-sclareolide
- 7 May 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (12) , 2009-2012
A study on the synthesis of antiangiogenic (+)-coronarin A and congeners from (+)-sclareolide